<DOC>
	<DOCNO>NCT02281084</DOCNO>
	<brief_summary>Evaluate safety efficacy CC-486 Durvalumab Subjects Myelodysplastic Syndromes fail achieve objective response post iHMA treatment</brief_summary>
	<brief_title>Safety Efficacy Study CC-486 Durvalumab Subjects With Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Male female , ≥ 18 year age time sign informed consent document 2 . Documented diagnosis MDS ( MYELODYSPLASTIC SYNDROMES ) , classify accord FAB ( FRENCHAMERICAN BRITISH ) classification criterion 3 . Adequate course treatment injectable hypomethylating agent ( azacitidine injection decitabine ) last therapeutic intervention MDS ( MYELODYSPLASTIC SYNDROMES ) prior begin screen study . Adequate define : receive least 6 consecutive 4week treatment cycle azacitidine injection , receive least 4 consecutive 6week treatment cycle decitabine ( 3day regimen ) least 6 consecutive 4week treatment cycle decitabine ( 5day regimen ) , demonstrate inability tolerate treatment injectable hypomethylating agent unacceptable drugrelated toxicity least 3 month attempt treatment : Three 28day cycle azacitidine injection decitabine 5day regimen ; two 42day cycle decitabine 3day regimen . 4 . Documented disease progression stable disease best response treatment ( attempted treatment ) azacitidine injection decitabine . Those achieve objective response recent treatment regimen injectable HMA ( HYPOMETHYLATING AGENT ) exclude participation study . Definitions disease progression modify IWG ( INTERNATIONAL WORKING GROUP ) 2006 criterion include : Preinjectable HMA ( HYPOMETHYLATING AGENT ) baseline bone marrow myeloblast : 1 . Less 5 % : ≥ 100 % increase ≥ 8 % blast 2 . ≥ 5 % : ≥ 50 % increase ≥ 10 % blast Note : ≥ 30 % blast consider AML ( ACUTE MYELOID LEUKEMIAT ) per FAB ( FRENCHAMERICAN BRITISH ) classification . Subjects know ≥ 30 % blast eligible inclusion study . RECOG ( Eastern Cooperative Oncology Group ) nizing limitation blast cell quantification , protocol allow subject preenrollment bone marrow blast count 33 % screen bone marrow examination consider inclusion . Assessment may make accord local bone marrow examination facilitate enrollment eligible subject treatment phase study . Any clinical worsening preinjectable HMA ( HYPOMETHYLATING AGENT ) baseline condition , include : a. sustain clinicallysignificant worsening ( investigator 's assessment ) baseline granulocyte , platelet , hemoglobin value ( ≥ 2 value , separate ≥ 2 week ) worsen granulocyte ≥ 50 % decrease preinjectable HMA ( HYPOMETHYLATING AGENT ) baseline value worsen platelet ≥ 50 % decrease preinjectable HMA ( HYPOMETHYLATING AGENT ) baseline value ( untransfused ) worsen hemoglobin ≥ 1.5 g/dL decrease preinjectable HMA ( HYPOMETHYLATING AGENT ) baseline value subject receive RBC ( RED BLOOD CELL ) transfusion b. meaningful worsen RBC ( RED BLOOD CELL ) platelet transfusion requirement Definition stable disease base modify IWG ( INTERNATIONAL WORKING GROUP ) 2006 criterion : Failure achieve objective response ( CR complete remission , PR partial remissino , mCR marrow complete remission , HI hematologic improvement ) , evidence disease progression within 8 week lead subject 's first dose IP ( INVESTIGATIONAL PRODUCT ) study ( Cycle 1 , Day 1 ) 5 . Have last dose prior treatment regimen ( injectable HMA ( HYPOMETHYLATING AGENT ) azacitidine injection decitabine ) 12 week prior screen study ( date inform consent signature ) . 6 . No less 3 week last dose prior treatment regimen ( injectable HMA ( HYPOMETHYLATING AGENT ) azacitidine injection decitabine ) plan date first dose IP ( IINVESTIGATIONAL PRODUCT ) . 7 . Have ECOG ( EASTERN COOPERATIVE ONCOLOGY GROUP ) performance status 0 , 1 , 2 8 . Females childbearing potential ( FCBP ) 1 may participate , provide meet following condition : Agree use least two effective contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; true abstinence ; vasectomized partner ) throughout study , 90 day follow last dose IP ( INVESTIGATIONAL PRODUCT ) ; Have negative serum pregnancy test ( sensitivity least 25 mIU/mL ) screening ; Have negative serum urine pregnancy test ( investigator 's discretion ) within 72 hour prior start treatment IP ( INVESTIGATIONAL PRODUCT ) ( Cycle 1 , Day 1 ) , begin subsequent cycle treatment . Note screen serum pregnancy test also use test prior start IP ( INVESTIGATIONAL PRODUCT ) perform within 72hour timeframe . 9 . Male subject female partner childbearing potential must agree use least two physicianapproved contraceptive method throughout course study avoid father child course study 90 day follow last dose IP ( INVESTIGATIONAL PRODUCT ) . 10 . Understand voluntarily sign informed consent document prior studyrelated assessment procedure conduct . 11 . Understand voluntarily sign biomarkerspecific component inform consent document prior studyrelated procedure conduct . 12 . Be able adhere study visit schedule protocol requirement 1 . Rapidlyprogressing MDS ( MYELODYSPLASTIC SYNDROMES ) , define : Known clinicallysignificant double marrow perIP ( INVESTIGATIONAL PRODUCT ) heral blood blast percentage ( ≥ 20 % ) 8week period lead first dose IP ( INVESTIGATIONAL PRODUCT ) ( Cycle 1 , Day 1 ) ≥100 % increase WBC count ( myeloid cell line monocyte series ) within 8week period lead Cycle 1 , Day 1 2 . Acute myelogenous leukemia ( AML ( ACUTE MYELOID LEUKEMIA ) FAB ( FRENCHAMERICANBRITISH ) classification : ≥ 30 % blast bone marrow ) . Subjects know ≥ 30 % blast eligible inclusion study . Recognizing limitation blast cell quantification , protocol allow subject preenrollment ( screening/baseline ) bone marrow blast count 33 % consider inclusion . 3 . Prior allogeneic autologous stem cell transplant 4 . Prior exposure investigational oral formulation decitabine , oral azacitidine derivative 5 . Prior ongoing response ( IWG ( International Working Group ) 2006 : hematologic improvement [ HI ] , partial response [ PR ] , complete remission [ CR ] , marrow CR ) treatment azacitidine injection decitabine , include relapsed disease 6 . Ongoing medically significant adverse event previous treatment , regardless time period 7 . Use follow within 28 day prior first dose IP ( INVESTIGATIONAL PRODUCT ) : thrombopoiesisstimulating agent ( [ TSAs ] ; eg , Romiplostim , Eltrombopag , Interleukin11 ) ESAs ( Erythropoiesis stimulate agent ) RBC ( Red blood cell ) hematopoietic growth factor ( eg , interleukin3 ) hydroxyurea 8 . Concurrent use corticosteroid unless subject stable decrease dose ≥ 1 week prior enrollment medical condition MDS ( MYELODYSPLASTIC SYNDROMES ) 9 . History inflammatory bowel disease ( eg , Crohn 's disease , ulcerative colitis ) , celiac disease ( ie , sprue ) , prior gastrectomy upper bowel removal , gastrointestinal disorder defect would interfere absorption , distribution , metabolism excretion IP ( INVESTIGATIONAL PRODUCT ) and/or predispose subject increase risk gastrointestinal toxicity 10 . Prior history malignancy , MDS ( MYELODYSPLASTIC SYNDROMES ) , unless subject free disease ≥ 3 year . However , subject follow history/concurrent condition allow : Basal squamous cell carcinoma skin Carcinoma situ cervix Carcinoma situ breast Incidental histologic find prostate cancer ( T1a T1b use tumor , node , metastasis [ TNM ] clinical staging system ) 11 . Significant active cardiac disease within previous 6 month , include : New York Heart Association ( NYHA ) class IV congestive heart failure ; Unstable angina angina require surgical medical intervention ; and/or Myocardial infarction 12 . Uncontrolled systemic fungal , bacterial , viral infection ( define ongoing signs/symptoms related infection without improvement despite appropriate antibiotic , antiviral therapy , and/or treatment ) 13 . Known Human Immunodeficiency Virus ( HIV ) Hepatitis C ( HCV ) infection , evidence active Hepatitis B Virus ( HBV ) infection 14 . Any following laboratory abnormality : Serum AST/SGOT ( Aspartate transaminase / Serum glutamic oxaloacetic transaminase ) ALT/SGPT ( Alanine aminotransaminase / Serum glutamic pyruvate transaminase ) &gt; 2.5 x ULN ( upper limit normal ) Serum total bilirubin &gt; 1.5 x ULN ( upper limit normal ) . Higher level acceptable attribute active red blood cell precursor destruction within bone marrow ( ie , ineffective erythropoiesis ) . Subjects exclude evidence autoimmune hemolytic anemia manifest correct reticulocyte count &gt; 2 % either positive Coombs ' test 50 % indirect bilirubin Serum creatinine &gt; 2.5 x ULN ( upper limit normal ) Absolute WBC ( white blood cell ) count ≥ 20 x 109/L 15 . Known suspected hypersensitivity azacitidine , mannitol , durvalumab , constituent , humanize monoclonal antibody 16 . Pregnant breastfeeding female 17 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study 18 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study 19 . Any condition confound ability interpret data study , include know suspected condition MDS ( MYELODYSPLASTIC SYNDROMES ) , associate anemia 20 . Having receive prior MAb ( monoclonal antibody ) CTLA4 ( cytotoxic T lymphocyteassociated antigen ) , PD1 , PDL1 receive investigational MAbs ( monoclonalantibodies ) within 6 month 21 . Clinical evidence central nervous system ( CNS ) pulmonary leukostasis , disseminate intravascular coagulation , CNS leukemia 22 . Current prior use immunosuppressive medication within 14 day prior first dose durvalumab . The following exception criterion : 1 . Intranasal , inhale , topical local steroid injection ( eg , intraarticular injection ) ; 2 . Systemic corticosteroid physiologic dos exceed 10 mg/day prednisone equivalent ; 3 . Steroids premedication hypersensitivity reaction ( eg , compute tomography [ CT ] scan premedication ) . 23 . Active prior document autoimmune inflammatory disorder ( include inflammatory bowel disease [ eg , colitis , Crohn 's disease ] , diverticulitis exception prior episode resolve diverticulosis , celiac disease , irritable bowel disease , serious gastrointestinal chronic condition associate diarrhea ; systemic lupus erythematosus ; Wegener 's syndrome [ granulomatosis polyangiitis ] ; myasthenia gravis ; Graves ' disease ; rheumatoid arthritis ; hypophysitis , uveitis ; etc ) within past 3 year prior start treatment . The following exception criterion : 1 . Subjects vitiligo alopecia ; 2 . Subjects hypothyroidism ( eg , follow Hashimoto syndrome ) stable hormone replacement ≥ 3 month ; 3 . Subjects psoriasis require systemic treatment 24 . History primary immunodeficiency 25 . Receipt live , attenuated vaccine within 30 day prior first dose durvalumab ( NOTE : Subjects , enrol , receive live vaccine study 30 day last dose durvalumab ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>azacitidine</keyword>
	<keyword>oral azacitidine ( CC-486 )</keyword>
	<keyword>decitabine</keyword>
	<keyword>intermediate-1</keyword>
	<keyword>intermediate-2 high risk myelodysplastic syndrome ( MDS )</keyword>
	<keyword>proliferative chronic myelomonocytic leukemia ( CMML )</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>hronic , Durvalumab , MEDI4736</keyword>
	<keyword>iHMA ( injectable hypomethylating agent )</keyword>
	<keyword>PD-L1</keyword>
</DOC>